Evotec

Navigating the Complexities of Cell-Based Therapies: Join Our VP at ISCT Europe 2024! The world of cell-based therapies is rapidly evolving, and regulatory challenges are at the forefront. Join our VP of ATMP Global Regulatory Affairs, Michela Gabaldo, as she chairs a crucial session on ATMP Regulatory Interplay at the upcoming ISCT Europe 2024 in Gothenburg! Why attend? - Gain insights into the difficulties in navigating quality and regulatory standards for cell-based starting materials. - Understand how to balance regulatory resilience and harmonization in this exciting field. Session Details: Date: Thursday, September 5th Time: 13:45 - 14:45 CET Interested in learning more about iPSC-based cell therapy or connecting with Michela? Contact us at info@evotec.com #ISCTEurope2024 #CellTherapy #ATMP #RegulatoryAffairs #iPSC

Step into the world of Evotec at CPhI Milan! Discover our tailored solutions and explore our API and drug product capabilities. Want to learn more about our API and drug product capabilities? Interested in our Just - Evotec Biologics development and #biomanufacturing services for #antibody & antibody-related therapeutics? Or perhaps our integrated continuous manufacturing platforms? And how about seeing our experts in action at our Verona site? Find all details here https://hubs.ly/Q02LpDl-0 - Don't wait to request a meeting or a site visit! #CPHI #drugdevelopment

Meet us in Estoril at Advanced Therapies Europe #ATE24! Evotec is supporting the event as an Associate Sponsor, and our colleagues Dr. Christine Guenther, EVP, Head of Global Cell Therapy Translation, Site Head Evotec Modena, and Michela Gabaldo, VP, ATMP Global Regulatory Affairs, are representing our approach and our expertise to deliver iPSC-based cell therapeutics within various sessions, including "Strategic Pathways: Optimizing Business Models for Emerging Biotech" and "Accelerating Cell and Gene Therapy Innovation: Regulatory Pathways in Europe". Read more details about our contributions here- https://hubs.ly/Q02LRXDx0 Please feel free to reach out to us if you would like to meet Christine, Michela, or our Business Development colleague Irving Donadon, PhD, MBA Donadon on site in Portugal. #AdvancedTherapiesEurope #CellTherapy

We are continuing our webinar series on hit identification strategies at Evotec. Please register now for episode 4 "The Role of Structural Insights in Drug Discovery". Join as as Dr. Jay Bertrand, Vice President, Head of Global Structural Biology and Evotec's Princeton Site Head, discusses the evolution of structural support to drug discovery projects, and provides insight into choosing the right protein for structural analysis. He will also share case studies on the application of X-ray and cryo-EM to obtain compound-bound protein structures. https://hubs.ly/Q02LpCrT0

Evotec SE today announced its financial results and corporate updates for the first half-year of 2024. Dr Christian Wojczewski, Chief Executive Officer of Evotec, said, ““During my first few weeks at Evotec, I have been hugely impressed by the dedication of our world-class talent base, the quality of our leading-edge technology platforms, and the deep partnerships with top pharma and biotech. We are an R&D powerhouse. Our science, our partnerships, and our people are the core strengths on which we will continue to build." To read his full quote and to learn more, read the press release here- https://hubs.ly/Q02Ld5Z80 #ResearchNeverStops #TogetherForMedicinesThatMatter

Join Us at Eurotox 2024! We are thrilled to invite you to two exciting events hosted by Evotec and Cyprotex at Eurotox 2024! Don't miss these opportunities to gain valuable insights and network with industry experts. Industry Hosted Session Topic: Navigating the Preclinical Development of Antibody Drug Conjugates (ADCs) Focus: Toxicology De-Risking Strategies for Enabling Personalized Medicine Date & Time: Monday, 9 September 2024, 12:00-13:00 Presenters: Dario Salerno, Senior Manager, Safety Assessment, and Giulia Iannoto, Immunotoxicologist, Safety Assessment Session Highlights: - Explore the complexities of ADCs, biopharmaceutical molecules designed to target cancer cells. - Understand the unique challenges in nonclinical safety assessment of ADCs. - Learn about the science-based approach to safety assessment and current regulatory guidelines. - Discover our recent case study and experiences with ADCs. Poster Presentation Title: Multiparametric In Vitro Assays Combined with High-Throughput RNA Sequencing for Cardiotoxicity Risk Assessment and Mechanistic Insight (#916) Date and time: Monday, 9 September 2024, 9:30am Presenter: Samantha Llewellyn, Associate Principal Scientist - Cyprotex Join us to delve into innovative methodologies for cardiotoxicity risk assessment and gain mechanistic insights through high-throughput RNA sequencing. Don't miss these sessions to stay at the forefront of toxicology and preclinical development. We look forward to seeing you there! #Eurotox2024 #ADCs #Toxicology #PreclinicalDevelopment #Cardiotoxicity #PersonalizedMedicine https://hubs.ly/Q02L3V0F0

Evotec SE today announced further strong progress of the company’s strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline. Performance-based and program-based achievements trigger payments of in total US$ 75 m to Evotec. To learn more, read the full press release here- https://hubs.ly/Q02L3H-r0 #TogetherForMedicinesThatMatter #ResearchNeverStops

Exciting News from the #Evotec in silico R&D Department! We are proud to announce a contribution to the field of computational biology with the introduction of a novel computational method called scBoolSeq d for the bidirectional linking of RNA-seq data and causal modeling of biological pathways. This tool was developed in collaboration with Institut Curie and Inria, and was published in the July 2024 issue of PLoS Computational Biology. scBoolSeq is designed to classify gene expression levels as either active (on) or inactive (off) using reference datasets. It can also generate synthetic scRNA-seq data that closely mimics the statistical properties of real datasets, leveraging causal mechanistic models of biological pathways. This innovative tool provides researchers with a means to enhance their understanding of gene activity, holding promise for applications in drug discovery, enabling the identification of new targets or biomarkers and clarifying the mechanisms of action for known targets. Figure depicts, Synthetic scRNA-seq dataset, generated from a hypothetical gene regulatory network model. The right panel visualizes the corresponding synthetic scRNA-seq dataset, generated based on the simulated network dynamics and displayed using the Principal Component Analysis (PCA) dimensionality reduction method. This visualization reveals a switch in cell fate decision programs, akin to observations in real-life scRNA-seq data. To learn more, read the paper here- https://lnkd.in/esdUHVzy #ComputationalBiology #GeneExpression #panomics #DrugDiscovery

Step into the world of Evotec at CPhI Milan! Discover our tailored solutions and explore our API and drug product capabilities. Want to learn more about our API and drug product capabilities? Interested in our Just - Evotec Biologics development and #biomanufacturing services for #antibody & antibody-related therapeutics? Or perhaps our integrated continuous manufacturing platforms? And how about seeing our experts in action at our Verona site? Find all details here https://hubs.ly/Q02Kzkpd0 - Don't wait to request a meeting or a site visit! #CPHI #drugdevelopment

Want to understand how we at Evotec consistently manage to find the perfect match from an infinite number of possibilities? Our cutting-edge hit identification technology guarantees "Quality Hits at Lightning Speed" - Learn more at https://hubs.ly/Q02KxNGk0 #researchneverstops #Evotec #HitIdentification #DrugDiscovery